# Kumquat Biosciences

Source: https://onco.cc/companies/kumquat-biosciences/  
OnCo record `kumquat-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kumquat Biosciences is a San Diego company founded by KRAS pioneers that makes pills against the KRAS cancer protein and immune-boosting small molecules. Its KRAS G12D drug entered human trials with Bayer in 2025.

## Summary

Kumquat Biosciences is a clinical-stage San Diego biotechnology company founded in 2018 by pioneers of KRAS targeting. Its lead asset, KQB548 (BAY 3771249), is a KRAS G12D inhibitor licensed to Bayer in August 2025 in a deal worth up to 1.3 billion US dollars in upfront and milestone payments plus royalties; a first-in-human phase 1 monotherapy trial (NCT07207707) in KRAS G12D-mutant tumours such as pancreatic, colorectal and lung cancer began in October 2025. Kumquat also granted Takeda an exclusive global licence to an oral immuno-oncology small molecule (up to 130 million US dollars near term and more than 1.2 billion in potential milestones) and has a discovery collaboration with Lilly on small molecules that stimulate tumour-specific immune responses. SEC Form D filings show about 56 million US dollars sold in 2019 and a further 80 million US dollars sold in 2021; round names are not disclosed.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Diego, CA
- Type: biotech
- Website: https://kumquatbiosciences.com/

## Notes

- Stage set to startup because no round beyond the 2021 Form D offerings was found; series labels and investors are not disclosed in fetched sources.

## Sources

- Official website: https://kumquatbiosciences.com/
- Bayer licence and collaboration (August 2025): https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-enter-global-exclusive-license-and-collaboration-in-precision-oncology/
- Phase 1 start with Bayer (October 2025): https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-initiate-phase-i-study-with-kras-g12d-inhibitor-in-patients-with-kras-mutated-tumors/
- Takeda collaboration: https://kumquatbiosciences.com/news/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- trials: [KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)](https://onco.cc/trials/nct07406633/)

---
JSON: https://onco.cc/api/v1/entities/kumquat-biosciences.json